Genomics

Dataset Information

0

SLCO1B1 Variants and Methotrexate Clearance


ABSTRACT:

Methotrexate plasma concentration is related to its clinical effects. To identify the genetic basis of interindividual variability in methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia (ALL), we performed a genome-wide analysis (GWAS) of 500,568 germline single-nucleotide polymorphisms (SNPs) in 434 children with ALL who received 3,014 courses of methotrexate at 2 to 5 g/m2. SNPs were validated in an independent cohort of 206 patients. Adjusting for age, race, sex, and methotrexate regimen, the most significant associations were with SNPs in the organic anion transporter polypeptide, SLCO1B1 (rs11045879 (P = 1.7 x 10-10) and rs4149081 (P = 1.7 x 10-9) (Trevino et al, PMID: 19901119). To test whether rare variants in SLCO1B1 could alter its function, we genotyped SLCO1B1 exons in a slightly larger group of 699 children with ALL who received methotrexate and identified 93 single nucleotide polymorphisms (SNPs). We found several common and rare non-synonymous (NS) SNPs associated with methotrexate clearance.

NS SNPs predicted to be functionally damaging (common or rare) were more likely to be found among patients with the lowest adjusted methotrexate clearance (lowest 10%) than patients with high clearance (highest 10%). Four SLCO1B1 haplotypes were associated with reduced methotrexate clearance and we verified that these haplotypes have lower function with in vitro transport assays. We were able to quantitatively account for a third of the population variability in clearance of methotrexate with clinical and genetic covariates. This data set includes the dependent variable of methotrexate clearance and all of the SNP data available from arrays, sequencing, and genotyping.

PROVIDER: phs000426.v1.p1 | EGA |

REPOSITORIES: EGA

altmetric image

Publications

Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.

Lopez-Lopez Elixabet E   Martin-Guerrero Idoia I   Ballesteros Javier J   Piñan M Angeles MA   Garcia-Miguel Purificacion P   Navajas Aurora A   Garcia-Orad Africa A  

Pediatric blood & cancer 20110308 4


<h4>Background</h4>Methotrexate (MTX) is an important component of the therapy for childhood acute lymphoblastic leukemia. Treatment with high-dose MTX often causes toxicity, recommending a dose reduction and/or cessation of treatment. Polymorphisms in genes involved in the MTX metabolism have been associated with toxicity with controversial results. The discrepancies could be due to differences in treatment protocols among studies, small, or non-homogeneous populations or the use of different t  ...[more]

Publication: 1/4

Similar Datasets

| phs000426 | dbGaP
| 2525144 | ecrin-mdr-crc
| phs000224.v1.p1 | EGA
2020-01-24 | E-MTAB-8399 | biostudies-arrayexpress
2024-03-18 | GSE254853 | GEO
2012-02-01 | E-GEOD-32124 | biostudies-arrayexpress
2012-02-01 | E-GEOD-32258 | biostudies-arrayexpress
2005-01-01 | MODEL1006230040 | BioModels
2022-02-24 | GSE196772 | GEO
2007-11-09 | E-GEOD-8052 | biostudies-arrayexpress